Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy
Despite significant improvements of new treatment options, cancer continues to represent as
one of the most common and fatal disease. The EGFR signaling pathway is considered as a …
one of the most common and fatal disease. The EGFR signaling pathway is considered as a …
Signaling pathway and small-molecule drug discovery of FGFR: a comprehensive review
Targeted therapy is a groundbreaking innovation for cancer treatment. Among the receptor
tyrosine kinases, the fibroblast growth factor receptors (FGFRs) garnered substantial …
tyrosine kinases, the fibroblast growth factor receptors (FGFRs) garnered substantial …
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
J Ye, J Wu, B Liu - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2023 - Elsevier
Despite some advances in targeted therapeutics of human cancers, curative cancer
treatment still remains a tremendous challenge due to the occurrence of drug resistance. A …
treatment still remains a tremendous challenge due to the occurrence of drug resistance. A …
Development of dual inhibitors targeting epidermal growth factor receptor in cancer therapy
L Tan, J Zhang, Y Wang, X Wang, Y Wang… - Journal of Medicinal …, 2022 - ACS Publications
Epidermal growth factor receptor (EGFR) is of great significance in mediating cell signaling
transduction and tumor behaviors. Currently, third-generation inhibitors of EGFR, especially …
transduction and tumor behaviors. Currently, third-generation inhibitors of EGFR, especially …
An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC)
Almost 80% of lung cancer diagnoses each year correspond to non-small cell lung cancer
(NSCLC). The percentage of NSCLC with EGFR overexpression ranges from 40% to 89 …
(NSCLC). The percentage of NSCLC with EGFR overexpression ranges from 40% to 89 …
Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization
A major problem associated with cancer treatment is resistance-prone chemotherapeutic
drugs. An increasing number of studies have documented that the occurrence of resistance …
drugs. An increasing number of studies have documented that the occurrence of resistance …
Nitrogen‐Containing Heterocyclic Scaffolds as EGFR Inhibitors: Design Approaches, Molecular Docking, and Structure‐Activity Relationships
Cancer is a wide collection of diseases and among the numerous pathways involved in
cancer pathogenesis, pathway involving epidermal growth factor receptor (EGFR) is one of …
cancer pathogenesis, pathway involving epidermal growth factor receptor (EGFR) is one of …
Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress
Epidermal growth factor receptor (EGFR) is a vital intermediate in cell signaling pathway
including cell proliferation, angiogenesis, apoptosis, and metastatic spread and also having …
including cell proliferation, angiogenesis, apoptosis, and metastatic spread and also having …
Discovery of anilino-1, 4-naphthoquinones as potent EGFR tyrosine kinase inhibitors: synthesis, biological evaluation, and comprehensive molecular modeling
Epidermal growth factor receptor (EGFR) has been recognized as one of the attractive
targets for anticancer drug development. Herein, a set of anilino-1, 4-naphthoquinone …
targets for anticancer drug development. Herein, a set of anilino-1, 4-naphthoquinone …
Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review
C Wang, Y Zhang, T Zhang, J Xu, S Yan, B Liang… - International Journal of …, 2023 - Elsevier
Overexpression of the epidermal growth factor receptor (EGFR) has been linked to several
human cancers, including esophageal cancer, pancreatic cancer, anal cancer, breast …
human cancers, including esophageal cancer, pancreatic cancer, anal cancer, breast …